Abstract:Heat shock proteins (HSP) when released into the extracellular milieu can act simultaneously as a source of antigen due to their ability to chaperone peptides and as a maturation signal for dendritic cells, thereby inducing DCs to cross-present antigens to CD8+ T-cells. HSP can also act independently from associated peptides, stimulating the innate immune system. Previous results regarding the activation of NK cells by HSP70 cell surface expression on tumour cells and soluble HSP70 will be further covered elsewhere within this issue. For cross-presentation, HSP70-peptide complexes (HSP70-PC) were used from two human melanoma cell lines that differ in the expression of the tumour-associated antigen tyrosinase. Purified HSP70-PC consists of both the constitutively expressed HSC70 and the inducible HSP70. HSP70-peptide complexes purified from tyrosinase positive (HSP70-PC/tyr+) human melanoma cells, incubated with immature DCs, results in the activation of HLA-*A0201-restricted tyrosinase peptide-specific T-cells. Receptor-mediated uptake of HSP70-PC by DCs and intracellular transport are required for efficient MHC class I restricted cross-presentation of chaperoned peptides. Demonstration of HSP70-PC mediated cross-presentation of such non-mutated naturally expressed tumour antigens is of special clinical interest with regard to hyperthermia. Tumour regression and improved local control have been shown within clinical phase II/III trials integrating regional hyperthermia combined with radiation and/or chemotherapy in multimodal treatment strategies. According to the proposed concept, local necrosis induced by hyperthermic treatment induces the release of HSPs, followed by uptake, processing and presentation of associated peptides by DCs. By acting as chaperone and a signal for DC maturation, HSP70-PC might efficiently prime circulating T-cells. Therefore, upregulating HSP70 and causing local necrosis in tumour tissue by hyperthermia offers great potential as a new approach to directly activate the immune system.

Re-evaluating the role of heat-shock protein–peptide interactions in tumour immunity

Heat Shock Protein–Peptide and HSP-Based Immunotherapies for the Treatment of Cancer

Roles of heat shock proteins in tumor immune microenvironment

The Interplay between Heat Shock Proteins and Cancer Pathogenesis: A Novel Strategy for Cancer Therapeutics

Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity

The HSP Immune Network in Cancer

Recent Advances in Heat Shock Protein-Based Cancer Vaccines

Heat Shock Proteins in the Immune System

Heat shock protein paradigms in cancer progression: future therapeutic perspectives

Heat shock protein 70: role in antigen presentation and immune stimulation

Heat shock proteins may be a missing link between febrile infection and cancer tumor rejection via autoantigen molecular mimicry

The heat-shock, or HSF1-mediated proteotoxic stress, response in cancer: from proteomic stability to oncogenesis

Membrane heat shock protein 70: a theranostic target for cancer therapy

The stress response regulator HSF1 modulates natural killer cell anti-tumour immunity

Revisiting the Old Data of Heat Shock Protein 27 Expression in Squamous Cell Carcinoma: Enigmatic HSP27, More Than Heat Shock

Heat Shock Proteins, a Double-Edged Sword: Significance in Cancer Progression, Chemotherapy Resistance and Novel Therapeutic Perspectives

Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach

Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies

Heat-shock proteins: new keys to the development of cytoprotective therapies

Heat Shock Proteins and HSF1 in Cancer

Roles of Extracellular HSPs as Biomarkers in Immune Surveillance and Immune Evasion